Paras Healthcare IPO October 2026: SEBI RHP, ₹1,450 Crore Offer and FY26 Financials

Summary: Paras Healthcare Limited’s red herring prospectus was listed by SEBI on 15 October 2026, with an abridged prospectus describing an offer of up to ₹1,450 crore: a fresh issue of up to ₹500 crore and an offer for sale of up to ₹950 crore. The document identifies an anchor investor bidding date of 19 October and a public offer period of 21–23 October 2026. The hospital operator reported FY26 consolidated revenue from operations of ₹1,605.952 crore and restated profit after tax of ₹43.834 crore, compared with a loss in FY25; its June 2026 quarter figures are also disclosed. The filing specifies debt-related uses for part of the fresh proceeds and details hospital capacity, operating metrics and business risks. This article examines those primary-source disclosures, distinguishes issuer proceeds from shareholder sale proceeds, and explains the general income-tax and GST framework for IPO equity transactions without discussing grey-market prices or projecting returns.

The Material IPO Development as of 17 October 2026

The Securities and Exchange Board of India (SEBI) lists Paras Healthcare Limited’s Red Herring Prospectus (RHP) under public-issue filings dated 15 October 2026. The corresponding SEBI-hosted abridged prospectus refers to an RHP dated 14 October 2026. These are different dates with different meanings: one identifies the underlying document and the other the regulator’s public filing entry. The company is the issuer; “Paras Health” is the brand under which the hospital network operates.

The article relies on the SEBI filing page and the SEBI-hosted abridged prospectus, rather than unofficial issue calendars, grey-market quotations or forward-looking subscription estimates. The abridged prospectus contains the stated offer structure, financial information and business risks, but certain pricing and final post-issue shareholding fields are marked as to be filled later. Accordingly, this article does not state a price band, application lot size, implied valuation or retail minimum investment amount as a verified fact.

IPO Size, Fresh Issue and Offer for Sale

The filed abridged prospectus states a total offer of up to ₹14,500 million, equivalent to ₹1,450 crore. The fresh issue component is up to ₹5,000 million, or ₹500 crore, while the offer for sale (OFS) is up to ₹9,500 million, or ₹950 crore. Equity shares have a face value of ₹1 each. The actual number of shares in certain offer fields depends on the final price and other finalisation steps, so the money amounts should not be mechanically converted into a share count.

The two OFS sellers identified in the document are promoter selling shareholder Dr. Dharminder Kumar Nagar, offering up to ₹300 crore, and investor selling shareholder Commelina Ltd, offering up to ₹650 crore. These amounts together reconcile to the ₹950 crore OFS. An OFS is a transfer by existing holders; it does not by itself bring that sale consideration into the issuing company’s bank account. This distinction is central to reading statements about the company’s capital raising and debt repayment.

Issue timetable and regulatory status

The document specifies Monday, 19 October 2026 for anchor investor bidding, Wednesday, 21 October 2026 for opening of the public offer, and Friday, 23 October 2026 for closing. The stated UPI mandate deadline is 5 p.m. on the closing date. The proposed listing venues are BSE and NSE, with NSE identified as the designated stock exchange. A filing with SEBI is not an endorsement of the securities: the prospectus expressly warns that SEBI does not approve or guarantee the accuracy or adequacy of the disclosures.

How Paras Healthcare Operates

Paras Healthcare describes itself as a clinical-specialty-led hospital platform offering tertiary and quaternary healthcare. At 30 June 2026, the network comprised eight hospitals and 2,211 total beds, including 559 ICU beds. The disclosed operational-bed figure was 1,502, which is not interchangeable with the larger total bed-capacity figure. The network had 1,084 doctors and 1,937 nurses as of that date. These are dated operating facts rather than assumptions about future expansion.

The hospitals are located in Gurugram, Panchkula, Patna, Darbhanga, Kanpur, Udaipur, Ranchi and Srinagar, across five states and one Union Territory. The group reports healthcare services as a single business segment and India as its single geographic segment. The document uses the term CONGOR for a collection of specialties including cardiac, oncology, neurosciences, gastroenterology, orthopaedics and sports injury, and renal sciences. These specialties accounted for 74.35% of revenue from operations for the June 2026 quarter.

The company’s revenue comes from inpatient services, outpatient services, pharmacy products and other operating income. The disclosed payor categories include self-pay patients, insurance and third-party administrators, and government schemes and public-sector undertakings. This mix matters when examining reimbursement cycles, claims processing and receivables; it is not equivalent to a guarantee of timely collection from any particular payor.

FY26 and June 2026 Quarter: Verified Financial Figures

The abridged prospectus reports restated consolidated financial information in ₹ million. For accessibility, the following table converts those amounts into ₹ crore by dividing by ten, without altering the source figures. FY26 denotes the year ended 31 March 2026, while the June 2026 quarter is the three months ended 30 June 2026. Quarter results must not be compared directly with full-year totals as if they covered the same period.

The source also reports FY24 revenue from operations of ₹1,129.039 crore and a restated loss after tax of ₹15.331 crore. FY26 therefore shows a move from the FY25 restated loss to a restated profit, but that historical improvement is not a prediction of subsequent profitability. FY26 EBITDA of ₹335.577 crore is defined in the prospectus by reference to profit or loss before tax plus finance costs and depreciation and amortisation; it is not the same as cash flow from operations.

For the three months ended June 2026, revenue from operations was ₹470.278 crore, versus ₹368.387 crore for the corresponding June 2025 quarter. Restated profit after tax was ₹49.682 crore, versus a loss of ₹1.024 crore in the comparative quarter. The Q1 FY27 operating cash flow was ₹64.338 crore and investing cash outflow was ₹92.018 crore. These amounts demonstrate why a profit-and-loss summary should be read alongside cash flow and borrowings.

Bed utilisation and operating indicators

The disclosed FY26 hospital bed-occupancy rate was 61.75%, compared with 50.78% for FY25. The three months ended June 2026 recorded occupancy of 69.72%, against 56.75% in the comparable quarter. The FY26 average revenue per occupied bed (ARPOB) was ₹47,397.82 per day, and the June 2026 quarter figure was ₹49,351.70. These metrics reflect the company’s specified methodology and the reported periods; they are not an estimate of individual patient bills or net margin per bed.

Where the Fresh Issue Proceeds Are Intended to Go

The company proposes to allocate ₹3,209 million (₹320.90 crore) of net proceeds towards prepayment or scheduled repayment, in full or in part, of certain outstanding borrowings availed by the company. A further ₹541 million (₹54.10 crore) is earmarked for investment in wholly owned subsidiary PMHPL, which also operates the Srinagar hospital, for repayment or prepayment of that subsidiary’s borrowings. The remaining amount is described under general corporate purposes and is subject to the applicable cap and final offer price.

Together, the two identified debt-related objects total ₹375 crore. This is an allocation disclosed in the filing, not proof that repayments have already occurred. The company’s borrowings at 30 June 2026 were ₹888.893 crore, so the prospective use of issue proceeds and the historical balance-sheet number should not be netted together as if they were contemporaneous completed transactions. The OFS proceeds of ₹950 crore belong to the selling shareholders and should not be counted as available for these company-level uses.

Risks and Qualifications in the RHP

Operating and financial risks

The prospectus describes exposure to clinical and patient-care risks, the cost of healthcare delivery, dependence on qualified doctors and staff, and the operational challenges of hospitals in different locations. A significant part of revenue is generated by core clinical specialties. Changes in case mix, demand, reimbursement terms or hospital operations may therefore affect results. These are risk disclosures made by the issuer, not findings that a specific adverse event has occurred.

Borrowings and capital expenditure are material to the financial position. At 31 March 2026, total borrowings of ₹854.101 crore were reported, and the June 2026 balance was ₹888.893 crore. The FY26 investing cash outflow of ₹239.410 crore was larger than FY26 operating cash flow of ₹163.512 crore. These amounts should be examined alongside financing cash flow, balance-sheet liabilities, cash balances and the debt-repayment objects rather than interpreted as a standalone solvency conclusion.

Payor mix and concentration

For FY26, government schemes and public-sector undertakings accounted for 41.28% of revenue from operations, insurance/TPA payors 24.84%, and self-pay patients 33.88%, as classified by the company. In the June 2026 quarter the corresponding shares were 43.63%, 25.07% and 31.30%. Reimbursement processing and collection patterns can differ across these groups. The filing also highlights geographic and hospital-level concentration, which should not be concealed by quoting only the overall network bed count.

The abridged prospectus contains a disclosure that the name of one promoter-group member appears in the CIBIL wilful-defaulter database. That is a prospectus risk disclosure about the named individual and should not be rewritten as a finding that Paras Healthcare Limited itself has been declared a wilful defaulter. The full wording and context in the prospectus control any republication of this sensitive matter.

IPO Tax and GST: What the Transaction Does and Does Not Trigger

Allotment, sale and capital gains

An IPO application and allotment are not, by themselves, a taxable capital gain for an ordinary investor merely because shares are allotted. A later transfer can generate a capital gain or loss, computed using the actual consideration, eligible cost and transfer expenses under the Income-tax Act, 2025. For equity shares listed on a recognised exchange, the long-term holding-period test is generally twelve months; the correct acquisition and transfer dates and the status of the holding must be determined from records.

For qualifying short-term gains from specified equity transactions on which the required securities transaction tax (STT) is paid, the Income-tax Act, 2025 contains a special 20% rate framework, subject to the applicable conditions, surcharge and cess. For qualifying long-term listed-equity gains, section 198 of that Act provides a 12.5% rate on the relevant aggregate gains exceeding ₹1.25 lakh, again subject to its STT requirements and statutory exceptions. The exemption threshold applies to aggregate eligible gains, not separately to each IPO application or share lot. Other cases may follow different rules, including non-resident and business-income situations.

Why equity subscription is not charged to GST

The CBIC’s sectoral GST FAQ explains that securities are excluded from the definitions of both goods and services under sections 2(52) and 2(102) of the CGST Act, 2017. Accordingly, GST is not charged merely on the issue or transfer of equity securities as such. This does not exempt all services connected with a securities transaction: brokerage and other taxable intermediary services can attract GST under their own classification and invoice rules. STT and stamp duty are distinct statutory levies and must not be described as GST.

What Is Verified and What Is Not Yet Stated Here

Verified from the SEBI-hosted filing are the RHP filing date, the offer split and ceiling, named OFS sellers, disclosed objects, the 19/21/23 October bidding dates, proposed exchanges, historical financial amounts and specified hospital metrics. The abridged document reviewed contains placeholders in price-band and some post-issue ownership fields. Those missing final figures are deliberately omitted. This is an editorial summary of disclosed facts, not an independent audit of the company or a confirmation of future allotment, listing or market prices.

Frequently Asked Questions

Q1. When was the Paras Healthcare RHP filed on SEBI’s website?

SEBI lists the RHP filing entry on 15 October 2026. The associated abridged prospectus refers to the underlying RHP dated 14 October 2026.

Q2. What is the verified total size of the offer?

The SEBI abridged prospectus describes an offer of up to ₹1,450 crore, comprising a fresh issue of up to ₹500 crore and an OFS of up to ₹950 crore.

Q3. When is the public offer scheduled to open and close?

The filed document states opening on 21 October 2026 and closing on 23 October 2026, with anchor investor bidding on 19 October 2026.

Q4. Does the entire ₹1,450 crore go to Paras Healthcare?

No. Only the fresh-issue component provides funds to the company, net of issue expenses. OFS proceeds go to the existing selling shareholders.

Q5. What was the company’s FY26 restated profit after tax?

The abridged prospectus reports FY26 restated consolidated profit after tax of ₹438.34 million, equivalent to ₹43.834 crore, compared with a FY25 loss of ₹57.983 crore.

Q6. Is GST charged on the shares issued in the IPO?

No GST applies to securities as such because securities are neither goods nor services under the CGST definitions. Separate taxable services, such as brokerage, have their own GST treatment.

Q7. Are IPO listing gains exempt from income tax?

No automatic exemption applies. A later sale can trigger capital gains or business-income taxation depending on the facts, holding period, STT and relevant Income-tax Act, 2025 provisions.

Key Takeaways

Paras Healthcare’s October 2026 RHP filing is a documented public-offer development, not a market-return event. The ₹1,450 crore maximum offer consists of ₹500 crore fresh issue and ₹950 crore OFS. The filing shows FY26 revenue of ₹1,605.952 crore, restated profit of ₹43.834 crore and borrowings of ₹854.101 crore at year-end, with further June 2026 figures and operating metrics. Two identified debt-related uses total ₹375 crore. The price band and lot size are not asserted here because they were not established from the reviewed primary document. Securities themselves are outside GST, while subsequent equity gains are governed by the applicable income-tax provisions.

****

Disclaimer: This article is an informational explanation of publicly filed disclosures and applicable general law, not an offer, solicitation, securities research recommendation, investment advice, valuation, assurance or prediction. The RHP and subsequent official updates control any issue terms, risks and financial figures; investors and other readers must independently verify current documents and their own tax circumstances. TaxGuru accepts no responsibility for any financial loss, tax consequence, application decision, trading outcome or reliance on this article.

Source Links

• SEBI Paras Healthcare RHP filing, 15 October 2026: https://www.sebi.gov.in/filings/public-issues/oct-2026/paras-healthcare-limited-rhp_105284.html
• SEBI Paras Healthcare abridged prospectus (18 pages): https://www.sebi.gov.in/sebi_data/commondocs/oct-2026/Paras%20Healthcare%20Limited_p.pdf
• Income-tax Act, 2025 official consolidated PDF: https://incometaxindia.gov.in/Documents/Act/Income-tax-Act-2025.pdf
• Income Tax Department section 198 (listed-equity LTCG): https://wmstatic-prd.incometaxindia.gov.in/web/guest/w/section-198-76
• CBIC sectoral GST FAQs (securities and GST): https://cbic-gst.gov.in/sectoral-faq.html